Revumenib achieved a 22.8% complete remission rate and a 63.2% overall response rate in KMT2Ar acute leukemia patients. The study involved 94 patients, with a median age of 37, and highlighted ...
Brukinsa demonstrated superior efficacy and cardiac safety over Imbruvica in CLL/SLL treatment, especially in high-risk patients with 17p deletions. The ALPINE phase 3 trial showed sustained ...